1.54% -0.50

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TEVA Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 49% One Year Share Price Jump - Sahm

Teva stock hits 52-week high at $32.02 - Investing.com

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm

Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound - Sahm

Top 2 Health Care Stocks That May Crash In Q1 - Sahm

The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS

Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies - GlobeNewswire Inc.

What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz

Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm

Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift - Sahm

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz

Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India

Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz

Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm

Teva Releases Q4 2025 Aide Memoire - Sahm

Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm

Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm

Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria

Teva Pharma stock hits 52-week high at 29.81 USD - Investing.com

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Teva stock hits 52-week high at 26.38 USD - Investing.com

Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz

Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria

Teva Pharma stock hits 52-week high at $25.96 - Investing.com

Teva (NYSE:TEVA) Valuation: Assessing Upside After Positive Earnings and Updated Long-Term Growth Targets - Sahm

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com

Teva Pharmaceutical ADR Clears Key Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

Why Teva Pharmaceutical Stock Rocked the Market Today - Finviz

Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm

Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com

Teva stock hits 52-week high at 23.07 USD - Investing.com

Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines

Simile a TEVA